PATENTS

How logically impossible patents block biosimilars

Deep patent portfolios help drugmakers block market entry by potential biosimilars, but many biologic patents logically cannot be valid barriers to competitive entry.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Chen, B. K., Yang, Y. T. & Bennett, C. L. Drugs 78, 1777–1781 (2018).

  2. 2.

    Biologic Patent Transparency Act, S.659 https://www.congress.gov/bill/116th-congress/senate-bill/659/text (2019).

  3. 3.

    Brennan, Z. Six lawsuits target AbbVie’s Humira and its patent thicket. Regulatory Focus https://www.raps.org/news-and-articles/news-articles/2019/4/six-lawsuits-target-abbvies-humira-and-its-patent (2 April 2019).

  4. 4.

    Metallizing Engineering Co. v. Kenyon Bearing & Auto Parts Co., 153 F.2d 516 (2d Cir. 1946).

  5. 5.

    21 USC § 372(d).

  6. 6.

    42 USC § 262(l).

  7. 7.

    Price, W. N. II & Rai, A. K. Science 348, 188–189 (2015).

  8. 8.

    Kapczynski, A. 59 UCLA L. Rev. 970 (2012).

  9. 9.

    Genentech files complaint against Pfizer regarding Herceptin. Big Molecule Watch https://www.bigmoleculewatch.com/2017/11/21/genentech-files-complaint-against-pfizer-regarding-herceptin/ (21 November 2017).

  10. 10.

    Overpatented, overpriced: special Humira edition. I-MAK http://www.i-mak.org/wp-content/uploads/2018/09/i-mak.humira.report.final_.0917.pdf (17 September 2018).

Download references

Acknowledgements

The authors thank B. Potter and B. Wright for research assistance. WNP’s work was supported by the Cook Fund at the University of Michigan Law School and the Novo Nordisk Foundation (NNF17SA0027784).

Author information

Correspondence to W. Nicholson Price II.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark